Dr. Scott Rocklage Ph.D has his office based out of Boston, Massachusetts. He joined 5AM in 2003. He has been a managing partner of 5AM Venture Management LLC since 2004. 5AM Ventures supports companies that are working on producing medical break-throughs that are important to healthcare needs. From May 11, 2006 to June 25, 2016 Dr Scott Rocklage served as the CEO (chief executive officer) at EPIRUS Biopharmaceuticals Inc. EPIRUS was created to help enhance the information provided when using pharmaceuticals and natural sources of treatment. He is the President and CEO of Nycomed Salutar. Nycomed Salutar is based in Sunnyvale California and was founded in 1983. Nycomed Salutar produces magnetic susceptibility-based MRI contrast. Dr. Scott Rocklage has over thirty years of healthcare management experience. He led the FDA in the approval of three new drug applications. He served as the chairman and CEO of Cubist Pharmaceuticals and was formerly the Executive Chairman of Ilypsa. Ilypsa developes polymer medicines that are used to treat conditions of the gastrointestional tract and kidney disease. He has his B.S in Chemistry from the University of California, Berkley. He has his Ph.D in Chemistry from MIT (Massachusetts Institute of Technology). He has conducted research in Richard R. Schrock’s laboratory. Richard Schrock is a Nobel Prize winner. Dr. Rocklage has over one hundred peer reviewed publications and has invented or co-invented over thirty U.S patents. He has a strategic leadership track record and a scientific background. Dr. Scott Rocklage has also entered many candidates into multiple drug clinical trials and learn more about Scott.
More visit: https://www.tumblr.com/blog/scottrocklage